ATE504595T1 - Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz - Google Patents

Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Info

Publication number
ATE504595T1
ATE504595T1 AT05784419T AT05784419T ATE504595T1 AT E504595 T1 ATE504595 T1 AT E504595T1 AT 05784419 T AT05784419 T AT 05784419T AT 05784419 T AT05784419 T AT 05784419T AT E504595 T1 ATE504595 T1 AT E504595T1
Authority
AT
Austria
Prior art keywords
diabetes
obesity
treatment
hyperlipidemia
hyperglycemia
Prior art date
Application number
AT05784419T
Other languages
English (en)
Inventor
Yu Huang
Xu Chen
Original Assignee
Generon Shanghai Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp filed Critical Generon Shanghai Corp
Application granted granted Critical
Publication of ATE504595T1 publication Critical patent/ATE504595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05784419T 2005-01-04 2005-08-08 Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz ATE504595T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100231030A CN100515491C (zh) 2005-01-04 2005-01-04 白介素-22的医药用途
PCT/US2005/028186 WO2006073508A1 (en) 2005-01-04 2005-08-08 Use of il-22 for the treatment of conditions of metabolic disorders

Publications (1)

Publication Number Publication Date
ATE504595T1 true ATE504595T1 (de) 2011-04-15

Family

ID=35066920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05784419T ATE504595T1 (de) 2005-01-04 2005-08-08 Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Country Status (9)

Country Link
US (4) US20100015086A1 (de)
EP (1) EP1841781B1 (de)
JP (1) JP5221959B2 (de)
CN (1) CN100515491C (de)
AT (1) ATE504595T1 (de)
AU (1) AU2005323392B2 (de)
CA (1) CA2592943C (de)
DE (1) DE602005027400D1 (de)
WO (1) WO2006073508A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976532B1 (de) * 2006-01-27 2015-11-11 Yale University Schnell handelnde hemmer der magensäuresekretion
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2010081112A1 (en) * 2009-01-12 2010-07-15 Yu Liang Huang Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
WO2013177432A1 (en) * 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN104623639A (zh) * 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
KR20210019464A (ko) 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
EP4106794A4 (de) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Verfahren zum behandeln der transplant-und-wirts-krankheit
EP4504052A4 (de) * 2022-04-01 2026-04-01 Massachusetts Gen Hospital Vektoren und verfahren zur behandlung von neurodegeneration, verzögerung des kognitiven abbaus und verbesserung des gedächtnisses
JP7760986B2 (ja) 2022-11-01 2025-10-28 トヨタ自動車株式会社 運転支援装置及び運転支援装置の処理方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
HU217871B (hu) * 1992-10-01 2000-04-28 Schering Corp. Eljárás hatóanyagként IL-10-et tartalmazó, inzulin-függő diabetes mellitus megelőzésére szolgáló gyógyszerkészítmények előállítására
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US20050271619A1 (en) * 1998-10-26 2005-12-08 Laure Dumoutier Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
WO2000024758A1 (en) * 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US20030235561A1 (en) * 2002-06-25 2003-12-25 Cell Based Delivery Inc. Vascularized organized tissues and uses thereof
US20040236075A1 (en) * 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
JP2007525438A (ja) * 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法

Also Published As

Publication number Publication date
EP1841781A1 (de) 2007-10-10
US20080069799A1 (en) 2008-03-20
EP1841781B1 (de) 2011-04-06
CN100515491C (zh) 2009-07-22
DE602005027400D1 (de) 2011-05-19
JP5221959B2 (ja) 2013-06-26
CN1679918A (zh) 2005-10-12
US7718604B2 (en) 2010-05-18
CA2592943A1 (en) 2006-07-13
US7696158B2 (en) 2010-04-13
US20080069798A1 (en) 2008-03-20
US20080138314A1 (en) 2008-06-12
AU2005323392A1 (en) 2006-07-13
WO2006073508A1 (en) 2006-07-13
AU2005323392B2 (en) 2011-08-18
US7666402B2 (en) 2010-02-23
CA2592943C (en) 2015-11-24
US20100015086A1 (en) 2010-01-21
EP1841781A4 (de) 2008-04-16
JP2008526740A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
WO2010049678A3 (en) Treatment of energy utilization diseases
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
HUE038279T2 (hu) Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
WO2007100535A3 (en) Oxyntomodulin derivatives
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
EP2118123A4 (de) Stabilisierte p53-peptide und deren verwendungen
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
IL200660A (en) Methods for producing 2,1-propanediol and e. coli is adapted to use these methods
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
DE602004020703D1 (de) Polycarbonatharzzusammensetzung und Polarisationsblatt welches diese verwendet
DE602005015841D1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
CL2008003182A1 (es) Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable.
BRPI0908569A2 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
HRP20110093T4 (hr) Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama
DE602005001576D1 (de) Pyrrolidin- und thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes
DK1605965T3 (da) Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties